+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-12-18Number of Pages: 104

Biotherapeutics Cell Line Development Market (by Process, CLD Option and by Geography): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022

With the increasing number of recombinant protein therapeutics gaining approval by the U.S. Food and Drug Administration (FDA) annually, there is an increase in the demand of cell lines for production of these biotherapeutics. From 2006 to 2011 an average of 15 novel recombinant protein therapeutics and in 2014, 11 novel recombinant protein therapeutics have been approved by US FDA. About forty-seven monoclonal antibody products have been approved in the U.S., Europe and other global markets, of which over 60% were produced in mammalian cell culture. Moreover, the rise in the geriatric population coupled with prevalence of diseases is one of the major factors driving the demand for cell line development for biotherapeutics. The increasing demand for monoclonal antibodies across the globe boosts the market growth. In addition, the increasing number of initiatives taken by the government of various countries by funding the life science research and development is expected to propel this market in coming years. 

The global biotherapeutics cell line development market is segmented by process, by cell line development option and by geography. The market by process segment has been sub-segmented as transfection and single cell cloning. The single cell cloning market is further sub-segmented by method into manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest market share of 37.4% in 2014. Geographically, the market has been studied and estimated for five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes market attractiveness analysis, by geography, to provide a thorough analysis of the overall competitive scenario in the global biotherapeutics cell line development market. The market overview section of the report also includes the qualitative and quantitative analysis of the competitive landscape. 

Market share analysis for FACS market is also provided in the market overview section of the report for 2014 in terms of value (%). The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the biotherapeutics cell line development market across the world. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Becton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.). 

The global biotherapeutics cell line development market has been segmented as follows: 

  • Global Biotherapeutics Cell Line Development Market, by Process
    • Transfection & Selection
    • Single Cell Cloning
      • Manual limited dilution cloning
      • FACS
      • ClonePix
      • Others
  • Global Biotherapeutics Cell Line Development Market, by CLD Option
    • In-house
    • Outsource
    • Hybrid
    • Do-It-Yourself (DIY) 
  • Global Medical Cameras and Microscopes Market, by Geography
    • North America
    • Europe
    • Asia Pacific (APAC)
    • Latin America (LATAM)
    • Middle East & Africa


Chapter 1  Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Biotherapeutics Cell Line Development Market
2.2 Comparative Analysis: Global Biotherapeutics Cell Line Development Market, by Geography, 2014 & 2022

Chapter 3 Biotherapeutics Cell Line Development Market Overview
3.1 Introduction
3.2 Market Dynamics
       3.2.1 Drivers
       3.2.2 Restraints
       3.2.3 Opportunities
3.3 Biotherapeutics Cell Line Development Sites: Qualitative Analysis, 2014
3.4 Market Attractiveness Analysis: Biotherapeutics Cell Line Development Market, by Geography, 2014
3.5 Competitive Landscape: FACS Market
       3.5.1 Market Share by Revenue, by Key Players, 2014 (Value %)

Chapter 4 Global Biotherapeutics Cell Line Development Market Revenue, by Process, 2014 – 2022 (USD Million)
4.1 Introduction
4.2 Transfection & Selection
4.3 Single Cell Cloning
       4.3.1 Manual Limited Dilution Cloning (e.g. Single Cell Imagers such as CloneSelect, etc.)
       4.3.2 FACS
       4.3.3 ClonePix

Chapter 5 Global Biotherapeutics Cell Line Development Market Revenue, by CLD Option, 2014 – 2022 (USD Million)
5.1 Introduction
5.2 In-house
5.3 Outsource
5.4 Do-it-yourself (DIY)
5.5 Hybrid

Chapter 6 Global Biotherapeutics Cell Line Development Market Revenue, by Geography, 2014 – 2022 (USD Million)
6.1 Introduction
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 Middle East & Africa (MEA)

Chapter 7 Recommendations
7.1 Past and Future Trends
7.2 Barriers to success

Chapter 8 Company Profiles
8.1 Becton, Dickinson and Company
       8.1.1 Company Overview
       8.1.2 Financial Overview
       8.1.3 Product Portfolio
       8.1.4 Business Strategies
       8.1.5 Recent Developments
8.2 Beckman Coulter, Inc. (Danaher Corporation)
8.3 Boehringer Ingelheim Pharma GmbH & Co KG.
8.4 Catalent, Inc.
8.5 CMC Biologics
8.6 Lonza Group Ltd.
8.7 Partec (Sysmex Corporation)
8.8 ProBioGen AG
8.9 SAFC (Sigma-Aldrich Corporation)
8.10 Selexis SA
8.11 Sony Biotechnology Inc. (Sony Corporation)
8.12 Thermo Fisher Scientific, Inc.
8.13 Others

As the biotherapeutics industry continues to grow exponentially, there has been an increase in the demand for mammalian cell line development. Big pharma companies have been aggressively pursuing the development of large molecule drugs by investing heavily in biotechnology. Moreover, with the increasing prevalence of diseases, there is an increase in the demand for biotherapeutics which consequently boosts the market for cell line development. According to the information by International Diabetes Federation (2014), the percentage of population suffering from diabetes across the globe would increase by 53% from 2014 to 2035. 

The global biotherapeutics cell line development market is segmented by process, by cell line development option and by geography. The market by process segment has been sub-segmented as transfection and single cell cloning. The single cell cloning market is further segmented by method as manual limited dilution cloning, FACS, ClonePix and Others. The market by CLD option is segmented as In-house, outsource, hybrid and do-it-yourself. The ClonePix accounted for the largest market share of 37.4% in 2014. 

Geographically, the market has been studied and estimated for five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the biotherapeutics cell line development market in 2014, followed by Europe. The largest market share of North America is attributed to growing demand due to increasing proportion of geriatric population and prevalence of diseases leading to increase in the demand of biotherapeutics and consequently cell line development. Asia Pacific was identified as the third largest market for biotherapeutics cell line development in 2014. The region is expected to register the fastest CAGR during the forecast period. Multinational biopharmaceutical manufacturers are making considerable investments in the region making it lucrative for the biotherapeutics cell line development.

Major players in this market are Becton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation, Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC. (U.S.), Sony Biotechnology Inc. (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

biotherapeutics-cell-line-development-2015-market

 


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries